Abstracts tagged "COVID-19"

Abstract Number: 0141 • ACR Convergence 2022
Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
Yasmin Gerais¹, Chenyu Sun¹, Bethany King², Scott Lowe³, Biniyam Mohammed¹, Rachel Bentley³, Yaru Li⁴, Binyu Wei⁵ and Chuanhui Xu⁶, ¹Ascension Saint Joseph hospital, Chicago, IL, ²MercyOne Des Moines Medical center, Des Moines, IA, ³College of Osteopathic Medicine, Kansas City University, Kansas, MO, ⁴Swedish Hospital, Chicago, IL, ⁵Harvard Medical School, Boston, MA, ⁶Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: Rituximab targets the CD20 antigen to deplete B cells and is indicated for a number of autoimmune diseases and other conditions. Accumulating data suggest…
Abstract Number: 0508 • ACR Convergence 2022
Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…
Abstract Number: 0751 • ACR Convergence 2022
Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Smruthi Ramachandran¹, Jenny Leese², Stephanie Therrien³, Catherine L. Backman¹, Jasmin Ma⁴, Kelly English⁵, Eileen Davidson⁶, Shanon McQuitty⁷, Alison Hoens⁵, Cheryl Koehn⁸, James Gavin⁹, jo Adams⁹ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, ⁷Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, ⁸Arthritis Consumer Experts, Vancouver, BC, Canada, ⁹University of Southampton, Southampton, United Kingdom
Background/Purpose: The COVID-19 pandemic has provided opportunity to increase integration of virtual healthcare with in-person medical practices. Individuals with rheumatoid arthritis (RA) continue to self-manage…
Abstract Number: 0786 • ACR Convergence 2022
Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
Carolina A Isnardi¹, Osvaldo Luis Cerda¹, MARGARITA LANDI², Leonel Cruces³, Emilce Edith Schneeberger¹, Claudia Calle montoro², Maria Agustina Alfaro⁴, Brian Manases roldan⁴, Andrea Belen Gomez Vara¹, Pamela Giorgis⁴, Roberto Alejandro Ezquer⁴, María G Crespo Rocha⁴, Camila R Reyes Gómez⁴, maria de los angeles correa⁴, Marcos Rosemffet⁵, Virginia Carrizo Abarza⁴, Santiago Catalan Pellet⁶, Miguel Perandones⁴, Cecilia Reimundes⁷, Yesica Longueira³, Gabriela Turk³, María Florencia Quiroga³, Natalia Laufer³, Rosana Quintana⁸, Maria De la Vega⁹, Nicolás Kreplak¹⁰, Marina Pifano¹⁰, Pablo Maid², Guillermo Pons-Estel¹¹ and Gustavo Citera¹, ¹Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ²Austral University Hospital, Rheumatology Department, Buenos Aires, Argentina, ³Universidad de Buenos Aires. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS). Facultad de Medicina, Buenos Aires, Argentina, ⁴Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁶Austral University Hospital, Rheumatology Department, Lincoln, Argentina, ⁷Austral University Hospital, Rheumatology Department, Pilar, Argentina, ⁸Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁹Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹⁰Ministry of Health of the Province of Buenos Aires, Buenos Aires, Argentina, ¹¹CREAR, Rosario, Argentina
Background/Purpose: Patients with immune mediated diseases achieve lower seroconversion rates to COVID19 vaccines compared to healthy controls, which is why these patients are a prioritized…
Abstract Number: 0838 • ACR Convergence 2022
Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
Lisa Mandl¹, Benjamin Swett¹, Robyn Lipschultz¹, Myriam Lin¹, Alison Zhao², Carola Hanreich¹, Dongmei Sun¹, Kethy Jules-elysee¹ and Friedrich Boettner¹, ¹Hospital for Special Surgery, New York, NY, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Background/Purpose: Over 520 million people have been infected by SARS-CoV-2. In 10-40%, disabling symptoms such as fatigue and dyspnea can persist. Risk factors for poor…
Abstract Number: 1201 • ACR Convergence 2022
Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
Emily G Oakes¹, Jack Ellrodt¹, Roberta Alexander², John Conklin², May Choi³, Hongshu Guan¹, Sara Tedeschi¹, Jeffrey Sparks⁴, Siobhan Case⁵, Tiffany Hsu¹, Daniel Solomon¹, Anna Jonsson¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Exagen, Inc., Vista, CA, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA
Background/Purpose: Onset of autoimmune connective tissue disease (CTD) after COVID-19 infection has been reported and complement activation has been implicated. We examined common autoimmune rheumatic…
Abstract Number: 1591 • ACR Convergence 2022
Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Sandra Sze-jung Wu¹, Gelareh Atefi², Meghan Moynihan³, Kristin Evans³, Liisa Palmer³, Michael Pollack², Christine Dube⁴ and Cassandra Calabrese⁵, ¹AstraZeneca, Hockessin, DE, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Torrington, CT, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…
Abstract Number: 1875 • ACR Convergence 2022
Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin
Sangmee Bae¹, emmanuelle Faure-Kumar¹, Jennifer Wang², Ani Shahbazian², linh Truong², Howard Yang², Maureen McMahon¹, John FitzGerald¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Medical Center, Los Angeles, CA, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Antibodies to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) have been reported in pooled donor plasma and intravenous immunoglobulin products (IVIG) since May 2020 (C…
Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 0145 • ACR Convergence 2022
Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases
Paula María Corbalan¹, MARIANA PERA¹, Ana Lucia Barbaglia², Maria Constanza Bertolaccini³, Luciana González Lucero⁴, Raul Sueldo⁵, Rosana Nieves Chehín⁶, Rodrigo Hernán Tomas-Grau⁶, Diego Ploper⁶, Esteban Vera Pinguitore⁷, César Luis Ávila⁷, Benjamín Socías⁷, Silvia Inés Cazorla⁸, Carolina Maldonado Galdeano⁸ and VERONICA BELLOMIO⁴, ¹Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, ²Hospital Padilla, Tucumán, Argentina, ³Hospital Padilla, San Miguel de Tucuman, Argentina, ⁴Hospital Padilla, San Miguel de Tucumán, Argentina, ⁵Hospital Ángel Cruz Padilla, Tucumán, Argentina, ⁶Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA), San Miguel de Tucumán, Argentina, ⁷Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA), San Miguel de Tucumán, Tucuman, Argentina, ⁸Centro de Referencia para Lactobacilos (CERELA), San Miguel de Tucumán, Tucuman, Argentina
Background/Purpose: Several trials have reported lower seroconversion rates in patients with autoimmune rheumatic diseases than in healthy patients. In Argentina, the vaccines against SARS-CoV-2 that…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0753 • ACR Convergence 2022
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
Koichi Sugihara¹, Risa Wakiya¹, Tomohiro Kameda¹, Hiromi Shimada¹, Shusaku nakashima¹, Mikiya Kato¹, Taichi Miyagi¹, mao mizusaki², Rina Mino¹ and Hiroaki Dobashi³, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan
Background/Purpose: BNT162b2 is the most commonly used COVID-19 vaccine in Japan. The safety and efficacy of the vaccine was demonstrated in the general population, but…
Abstract Number: 0787 • ACR Convergence 2022
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Sara Tedeschi¹, Daniel Solomon¹, Yuezhou Chen², Jack Ellrodt¹, Mary Grace Whelan¹, Jacklyn Stratton¹, Keigo Hayashi³, Noah Whiteman², Lin Chen¹, Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Emma Gomez-Rivas¹, Deepak Rao¹, Anna Jonsson¹ and Duane Wesemann², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: DMARDs that treat RA may reduce immune responses to COVID-19 vaccination. We compared measures of humoral and cell-mediated immunity in RA patients before and…
Abstract Number: 0861 • ACR Convergence 2022
Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Amanda Neikirk², Yiling Yang², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on how rates of diagnosis of rheumatic diseases have changed during the COVID-19 pandemic. We compared rates of JIA diagnosis before…
Abstract Number: 1205 • ACR Convergence 2022
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases
Claire Cook¹, Naomi Patel², Xiaoqing Fu¹, Xiaosong Wang³, Yumeko Kawano³, Kathleen Vanni³, Grace Qian³, Emily Banasiak³, Emily Kowalski³, Hyon Choi⁴, yuqing zhang⁵, Jeffrey Sparks⁶ and Zachary Wallace¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Brigham and Women's Hospital, Boston, MA, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) on immunomodulatory medications may be at particular risk for COVID-19 breakthrough infection given uncertain immune response to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].